Nova
Executive Summary
Signs agreement with Grosse Pointe, Michigan-based Mediventures covering the development of approved psychiatric drugs using Mediventures' Quicksolv fast-dissolving drug delivery technology. Nova currently markets a line of psychiatric drugs -- Thorazine, Stelazine, Eskalith and Parnate -- obtained from SmithKline Beecham in a deal completed in July.
Signs agreement with Grosse Pointe, Michigan-based Mediventures
covering the development of approved psychiatric drugs using
Mediventures' Quicksolv fast-dissolving drug delivery technology.
Nova currently markets a line of psychiatric drugs -- Thorazine,
Stelazine, Eskalith and Parnate -- obtained from SmithKline Beecham
in a deal completed in July. |